Market closed
Cassava Sciences/$SAVA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Cassava Sciences
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia.
Ticker
$SAVA
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
29
Website
Cassava Sciences Metrics
BasicAdvanced
$1.3B
Market cap
-
P/E ratio
-$1.37
EPS
-0.57
Beta
-
Dividend rate
Price and volume
Market cap
$1.3B
Beta
-0.57
52-week high
$42.20
52-week low
$8.79
Average daily volume
1.7M
Financial strength
Current ratio
4.069
Quick ratio
3.797
Management effectiveness
Return on assets (TTM)
-37.43%
Return on equity (TTM)
-8.35%
Valuation
Price to book
6.75
Price to tangible book (TTM)
6.75
Price to free cash flow (TTM)
-13.345
Growth
Earnings per share change (TTM)
-37.60%
3-year earnings per share growth (CAGR)
52.92%
What the Analysts think about Cassava Sciences
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Cassava Sciences stock.
Cassava Sciences Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Cassava Sciences Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Cassava Sciences News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Cassava Sciences stock?
Cassava Sciences (SAVA) has a market cap of $1.3B as of November 08, 2024.
What is the P/E ratio for Cassava Sciences stock?
The price to earnings (P/E) ratio for Cassava Sciences (SAVA) stock is 0 as of November 08, 2024.
Does Cassava Sciences stock pay dividends?
No, Cassava Sciences (SAVA) stock does not pay dividends to its shareholders as of November 08, 2024.
When is the next Cassava Sciences dividend payment date?
Cassava Sciences (SAVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Cassava Sciences?
Cassava Sciences (SAVA) has a beta rating of -0.57. This means that it has an inverse relation to market volatility.